Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
Messer Plans Berryville, Arkansas, Air Separation Operations
01/16/2025
NewGlobal Ventures Plans Estancia Valley, New Mexico, Canning Operations
01/16/2025
Oxeon Energy Expands Davis County, Utah, Production Operations
01/13/2025
Nucor Towers & Structures Plans Brigham City, Utah, Production Operations
01/13/2025
Canada-Based Markdom Michigan Plastics Plans Charlotte, Michigan, Production Operations
01/13/2025
Japan-Based Nitto Plans Frankfort, Kentucky, Operations
01/12/2025
Most Read
-
2024's Leading Metro Locations: U.S. Cities on the Rise Amid an Economic Reshuffling
Q4 2024
-
The Workforce Factor: How States Are Competing to Build Tomorrow's Talent
Q4 2024
-
Best Practices in Incentives Procurement
Q4 2024
-
Five Strategies to Tackle the Data Center Talent Shortage
Q4 2024
-
Microsoft-Three Mile Island Deal Could Signal Path for Nuclear Power to Strengthen Partnerships with Big Tech
Q4 2024
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Why Decarbonization Goals Start with Site Selection
Q4 2024